Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success? |
| Type de publication | Journal Article |
| Year of Publication | 2018 |
| Auteurs | Pivot X, Cox DG, Gligorov J |
| Journal | CHINESE CLINICAL ONCOLOGY |
| Volume | 7 |
| Pagination | 1 |
| Date Published | FEB |
| Type of Article | Editorial Material |
| ISSN | 2304-3865 |
| DOI | 10.21037/cco.2017.10.07 |